Skip to content

ICAAC: HIV / HCV coinfected patients with fibrosis get little benefit and a lot of side-effects from interferon / ribavirin

ICAAC: Pegylated interferon-alpha 2a produces good results in HIV / HCV patients with genotype 1

An integrated approach to HIV and TB care in adults in resource-limited settings, part 1

ICAAC: Rapid HIV disease progression in injecting drug users in Ukraine

ICAAC: Tipranavir / ritonavir superior to other boosted PIs in salvage therapy

ICAAC: Kaletra: stability and potency decline rapidly in hot climates

ICAAC: Tolerability key to superior showing of tenofovir/FTC in head to head match with Combivir

ICAAC: Glaxo unveils chemokine blocker as interest in new drug class hots up

US HIV treatment guidelines revised